A cirrhosis workup is the combination of history-taking, physical examination, blood tests, imaging, and sometimes biopsy that clinicians use to confirm whether cirrhosis is present, identify what caused it, gauge how advanced it is, and screen for complications. There is no single test that settles the question on its own. Instead, findings from several different angles are layered together, and the workup continues to evolve as the disease is monitored over time. What surprises many people is that much of the evaluation now relies on non-invasive tools rather than the liver biopsy that was once considered essential.
What Doctors Look for on Physical Exam
The clinical evaluation starts with the body. Certain physical signs raise suspicion for cirrhosis well before any lab results come back. Spider nevi, which are small clusters of blood vessels visible on the skin of the upper body, are among the most studied bedside clues. A large meta-analysis covering more than 19,000 patients found that the presence of spider nevi roughly quadrupled the likelihood of cirrhosis, while the presence of ascites (fluid in the abdomen) increased the likelihood about sevenfold.1JAMA. Does This Patient With Liver Disease Have Cirrhosis? Other signs clinicians look for include palmar erythema (reddened palms), jaundice, gynecomastia in men, and an enlarged or shrunken liver on palpation. Notably, the absence of an enlarged liver also carried diagnostic weight in that same analysis, making cirrhosis less likely.
When ascites is suspected, flank dullness on percussion is the classic bedside finding.2PubMed. Physical examination of chronic liver disease and cirrhosis Still, no single physical sign is sensitive enough to rule cirrhosis in or out by itself. Many people with early, compensated cirrhosis look and feel perfectly healthy. That is why the exam is just one piece of the workup, always paired with laboratory data and imaging.
Blood Tests and What They Reveal
Routine liver blood tests are usually the first objective data a doctor has. These include bilirubin, the liver enzymes ALT and AST, alkaline phosphatase, GGT, serum albumin, and prothrombin time (often reported as INR).3Journal of Clinical and Experimental Hepatology. Value of Liver Function Tests in Cirrhosis Each of these markers tells a slightly different story. Bilirubin and albumin reflect how well the liver is actually functioning: high bilirubin and low albumin suggest the organ is struggling. Elevated AST and ALT signal ongoing liver-cell damage. A prolonged prothrombin time means the liver is not making clotting factors adequately.
A low platelet count is another important clue. Platelets drop in cirrhosis partly because the spleen enlarges from increased portal pressure and traps them. That same large meta-analysis found that a platelet count below about 160,000 per microliter increased the likelihood of cirrhosis roughly sixfold, while a count above that level made cirrhosis considerably less likely.4JAMA. Does This Patient With Liver Disease Have Cirrhosis?
Beyond confirming that liver disease exists, blood tests help identify what is causing it. A full etiologic workup typically includes hepatitis B and C serologies, iron studies for hemochromatosis, ceruloplasmin for Wilson disease, autoimmune antibodies, and sometimes alpha-1 antitrypsin levels. In rare cases, more than one cause can be present simultaneously, which makes systematic screening important even after one etiology has been found.5PubMed Central. Simultaneous Occurrence of Wilson’s Disease, Autoimmune Hepatitis, and Hereditary Hemochromatosis: A Diagnostic Challenge
Non-Invasive Fibrosis Scores
Two simple blood-based scores have become standard screening tools for fibrosis and cirrhosis. The FIB-4 index uses age, AST, ALT, and platelet count. The APRI score uses AST and platelet count. Both can be calculated from routine blood work, which makes them easy to apply in primary care before a patient ever sees a specialist.
How well do they perform? In one study of patients with chronic hepatitis C, FIB-4 outperformed APRI for detecting advanced fibrosis, with an area under the curve of about 0.88 compared to 0.84 for APRI.6PubMed Central. APRI and FIB-4 performance to assess liver fibrosis against predefined Fibroscan values in chronic hepatitis C virus infection But performance varies depending on the population being studied. In a large cohort from a U.S. insurance database, FIB-4 had only about 41% sensitivity for detecting cirrhosis at the time of diagnosis, though its specificity was above 90%.7JHEP Reports. FIB-4 and APRI for cirrhosis detection in a privately insured national cohort APRI was even less sensitive, catching fewer than one in ten cirrhosis cases in that same analysis. Another study found c-statistics of 0.73 for FIB-4 and 0.68 for APRI when predicting cirrhosis against biopsy or ultrasound findings.8PubMed Central. Accuracy of ultrasound and noninvasive markers of fibrosis to identify patients with cirrhosis
The takeaway is that these scores are better at ruling cirrhosis out when they are low than at ruling it in when they are high. A low FIB-4 is reassuring; a high one warrants further investigation, not a firm diagnosis. They are triage tools, not final answers.
Transient Elastography and Liver Stiffness
Transient elastography, most commonly performed with the FibroScan device, measures how stiff the liver is by sending a vibration pulse into the organ and tracking how fast the resulting wave travels. Stiffer tissue means more scarring. This technique has become one of the most important tools in the cirrhosis workup because it is painless, takes just minutes, and gives a quantitative result in kilopascals (kPa).
For diagnosing cirrhosis specifically, the published literature shows excellent accuracy. A large prospective study in patients with chronic liver disease found an area under the ROC curve of 0.96 for detecting biopsy-confirmed cirrhosis, with a cutoff of about 17.6 kPa yielding positive and negative predictive values around 90%.9PubMed Central. Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study A separate meta-analysis using a lower cutoff of 14.6 kPa reported a negative predictive value of 96%, meaning the test was very reliable at ruling cirrhosis out.10PubMed. Accuracy of liver stiffness measurement for the diagnosis of cirrhosis in patients with chronic liver diseases That difference in cutoff values reflects variations across disease causes and patient populations, but the direction is consistent: elastography is better at excluding cirrhosis than at confirming it when stiffness is borderline.
Beyond just diagnosing cirrhosis, liver stiffness measurements help stratify risk for complications. Higher readings correlate with the presence of large esophageal varices, prior ascites, and even hepatocellular carcinoma, with progressively higher thresholds mapping onto more severe disease.11PubMed Central. Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study This makes elastography useful not just once at the beginning but as an ongoing monitoring tool.
Imaging the Liver
Abdominal ultrasound is typically the first imaging study ordered when liver disease is suspected. It is cheap, widely available, and involves no radiation. Ultrasound can show a nodular liver surface, an enlarged spleen, visible collateral blood vessels, and free fluid in the abdomen, all of which suggest cirrhosis. With an experienced operator, accuracy for diagnosing severe fibrosis or cirrhosis can reach about 85%.12PubMed. Liver fibrosis, cirrhosis, and cirrhosis-related nodules: Imaging diagnosis and surveillance CT and MRI offer more detailed views of liver morphology and are particularly useful for characterizing suspicious liver nodules, assessing vascular anatomy before transplant evaluation, or when ultrasound is technically limited by body habitus or bowel gas.13PubMed Central. Prediction of liver cirrhosis, using diagnostic imaging tools
Screening for chronic liver disease in general practice should ideally include history, physical examination, serum transaminase measurement, upper abdominal ultrasonography, and in some cases transient elastography.14PubMed Central. The etiology, diagnosis and prevention of liver cirrhosis: part 1 of a series on liver cirrhosis Together, these steps cover the ground between suspicion and diagnosis without requiring a biopsy in most cases.
When Liver Biopsy Is Still Needed
Given the accuracy of non-invasive tools, liver biopsy is no longer the default step in every cirrhosis workup. But it remains valuable in specific situations. If blood tests and imaging leave the diagnosis uncertain, or if the underlying cause of the liver disease cannot be identified by other means, biopsy provides a direct look at tissue architecture. Studies have found that histology pointed to a specific diagnosis in about 84% of patients with persistently abnormal liver tests of unclear cause.15PubMed Central. The utility of liver biopsy in 2020
Biopsy also plays a role when features overlap between cirrhosis and other conditions. Noncirrhotic portal hypertension, for example, can mimic cirrhosis on imaging and even on elastography, and liver biopsy may be the only way to tell the two apart definitively.16PubMed. Noncirrhotic portal hypertension: current trends and future directions
The procedure is not without risk. Pain is the most common side effect, and serious bleeding can occur, though it is uncommon. For patients who have significant clotting problems, ascites, or obesity, a transjugular approach (threading a catheter through the jugular vein to the liver) is often preferred over the standard percutaneous (through the skin) route.17PubMed Central. Transjugular diagnostic procedures in hepatology: Indications, techniques and interpretation The transjugular route also allows measurement of the hepatic venous pressure gradient, which is useful for assessing portal hypertension.
Screening for Varices and Portal Hypertension
Once cirrhosis is confirmed, the workup shifts toward identifying complications. Portal hypertension, the rise in pressure within the portal vein system caused by resistance to blood flow through the scarred liver, drives many of the dangerous complications of cirrhosis. Among the most feared is bleeding from esophageal varices, the dilated veins that form when blood reroutes around the obstructed liver.
The traditional approach was to perform an upper endoscopy on every patient with cirrhosis to check for varices. But the Baveno VI and VII guidelines have refined this. Patients with a liver stiffness below 20 kPa and a platelet count above 150,000 per microliter have a very low risk of having varices that need treatment, and endoscopy can safely be avoided in this group.18Journal of Hepatology. Baveno VII – Renewing consensus in portal hypertension Validation studies have confirmed that no patients meeting these criteria had high-risk varices requiring intervention, achieving 100% negative predictive value.19PubMed Central. Validating and expanding the Baveno VI criteria for esophageal varices in patients with advanced liver disease: a multicenter study Patients who do not meet these criteria should undergo endoscopy.20PubMed. Validation of Baveno VI Criteria for Screening and Surveillance of Esophageal Varices in Patients With Compensated Cirrhosis and a Sustained Response to Antiviral Therapy
The hepatic venous pressure gradient (HVPG), measured during a transjugular procedure, is the gold standard for quantifying portal hypertension. A gradient below 10 mmHg is associated with a roughly 90% probability of remaining free of clinical decompensation over a median follow-up of four years.21PubMed. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis Above that threshold, the risk of developing ascites, variceal bleeding, or encephalopathy climbs considerably. HVPG measurement is not routine in every patient, but it provides powerful prognostic information in those being evaluated for transplant or experimental therapies.
Hepatocellular Carcinoma Surveillance
Cirrhosis is the strongest risk factor for hepatocellular carcinoma (HCC), and guidelines recommend ongoing surveillance for every patient with established cirrhosis. The standard approach is abdominal ultrasound every six months. A meta-analysis found that ultrasound alone detected HCC at any stage with about 84% sensitivity, but its sensitivity for catching early-stage tumors dropped to around 47%.22PubMed Central. Surveillance Imaging and Alpha Fetoprotein for Early Detection of Hepatocellular Carcinoma in Patients With Cirrhosis: A Meta-analysis Adding alpha-fetoprotein (AFP), a blood marker, to ultrasound improved early-stage detection to about 63% sensitivity, a meaningful gain.23PubMed Central. Surveillance Imaging and Alpha Fetoprotein for Early Detection of Hepatocellular Carcinoma in Patients With Cirrhosis: A Meta-analysis A separate study confirmed that combining AFP with ultrasound produced the highest diagnostic accuracy, with an area under the curve approaching 0.90.24PubMed Central. Utility of Alpha-Fetoprotein and Ultrasound in the Diagnosis and Prognosis of Patients with Hepatocellular Liver Cancer
Because early detection of HCC substantially improves treatment options and survival, most hepatologists now use ultrasound plus AFP together as a surveillance pair. When a suspicious nodule is found, contrast-enhanced CT or MRI follows to characterize it.
Evaluating Complications Beyond Varices
Ascites, the accumulation of fluid in the abdominal cavity, is the most common major complication of cirrhosis. When it first appears, a diagnostic paracentesis (withdrawing fluid with a needle) is recommended. The fluid is analyzed for cell count, albumin, protein, and culture. A serum-ascites albumin gradient above 1.1 g/dL confirms that the ascites is related to portal hypertension rather than another cause such as malignancy or infection.25PubMed. An evidence-based manual for abdominal paracentesis Simultaneously, a polymorphonuclear cell count of 250 or more per cubic millimeter in the fluid is the most sensitive marker for spontaneous bacterial peritonitis, a life-threatening infection that can develop in cirrhotic ascites.26PubMed. An evidence-based manual for abdominal paracentesis Abdominal ultrasound, diagnostic paracentesis, and ascitic fluid cultures are recommended across major guidelines, especially when infection is suspected.27European Journal of Gastroenterology & Hepatology. The clinical management of abdominal ascites, spontaneous bacterial peritonitis and hepatorenal syndrome
Kidney function requires close watching. Acute kidney injury is common in cirrhosis and sometimes progresses to hepatorenal syndrome (HRS), a condition where kidney function declines not because of structural kidney damage but because of circulatory changes driven by portal hypertension. HRS is diagnosed when kidney function drops and there is no evidence of intrinsic kidney disease such as blood in the urine, significant protein in the urine, or abnormal kidney ultrasound findings.28BMJ. Hepatorenal syndrome: pathophysiology, diagnosis, and management Updated consensus criteria require a rise in serum creatinine of at least 0.3 mg/dL within 48 hours or a 50% increase from baseline within seven days, combined with a failure to improve after adequate fluid resuscitation.29Journal of Hepatology. Acute kidney injury and hepatorenal syndrome in cirrhosis: Consensus recommendations of the International Club of Ascites and Acute Disease Quality Initiative Unlike most other forms of kidney injury, HRS can potentially be reversed with liver transplantation or vasoconstrictor drugs.
Hepatic encephalopathy, the cognitive impairment that results from the liver’s inability to clear toxins such as ammonia, ranges from subtle attention deficits to outright confusion and coma. The obvious forms are diagnosed clinically: confusion, disorientation, asterixis (a flapping tremor of the hands). Minimal hepatic encephalopathy, which has no overtly visible symptoms but impairs driving ability, reaction time, and quality of life, requires psychometric testing to detect. The Psychometric Hepatic Encephalopathy Score (PHES), a set of five paper-and-pencil tests, is the standard tool for this purpose.30Journal of Hepatology. Diagnosis and management of minimal hepatic encephalopathy Computerized tests are also being adopted due to their reliability on repeat testing.31PubMed Central. The diagnosis and treatment of minimal hepatic encephalopathy
Prognostic Scoring Systems
Once cirrhosis is established, two scoring systems dominate clinical decision-making. The Child-Pugh score uses five variables: bilirubin, albumin, INR, ascites, and encephalopathy. It classifies patients into class A (well-compensated), B (significant functional compromise), or C (decompensated). The MELD score, which stands for Model for End-Stage Liver Disease, uses bilirubin, INR, and creatinine in a mathematical formula. MELD was originally developed to predict survival after a specific procedure, but it has become the primary tool for liver transplant organ allocation in many countries.
Which score is better? A systematic review and meta-analysis found that they have broadly similar prognostic ability in most clinical scenarios, though each performed slightly better in specific subgroups. In patients admitted to intensive care, MELD was somewhat more sensitive, while Child-Pugh had higher specificity in surgical candidates.32PubMed Central. Child-Pugh Versus MELD Score for the Assessment of Prognosis in Liver Cirrhosis: A Systematic Review and Meta-Analysis of Observational Studies Another study found the scores performed similarly for predicting in-hospital death from upper gastrointestinal bleeding in cirrhosis, with areas under the curve of about 0.80 and 0.81 respectively.33PubMed Central. Child-Pugh versus MELD score for predicting the in-hospital mortality of acute upper gastrointestinal bleeding in liver cirrhosis In practice, most clinicians use both. Child-Pugh gives a quick bedside sense of disease severity, while MELD drives transplant listing decisions.
When the Picture Looks Like Cirrhosis But Is Not
Not every patient with portal hypertension, varices, and a dysmorphic-looking liver on imaging has cirrhosis. Noncirrhotic portal hypertension (NCPH) is a collection of vascular liver disorders that can closely mimic cirrhosis clinically and radiologically. Some patients with NCPH are misdiagnosed as having cryptogenic cirrhosis because the overlap in features is so convincing.34PubMed. Noncirrhotic Portal Hypertension: Current Concepts and Overview of Causes, Pathophysiology, and Imaging Findings Causes include portal vein thrombosis, nodular regenerative hyperplasia, and porto-sinusoidal vascular disorder.
Distinguishing NCPH from true cirrhosis matters because the prognosis and management differ. Liver stiffness and splenic stiffness measurements can help, since liver stiffness in NCPH tends to be lower than in established cirrhosis, but liver biopsy remains important for confirmation.35PubMed. Noncirrhotic portal hypertension: current trends and future directions The workup should consider this possibility especially when the liver stiffness is only mildly elevated but the patient has significant portal hypertension, or when no clear cause of cirrhosis can be identified.
Acute-on-Chronic Liver Failure
For patients with known cirrhosis who suddenly deteriorate, a different diagnostic framework kicks in. Acute-on-chronic liver failure (ACLF) is defined by rapid clinical worsening in a patient with chronic liver disease, with rising bilirubin and INR plus failure of at least one organ system outside the liver, such as the kidneys, brain, or cardiovascular system.36Hepatology. AASLD Practice Guidance on Acute-on-chronic liver failure and the management of critically ill patients with cirrhosis ACLF is graded into stages based on how many organ systems are failing, with higher grades carrying dramatically worse short-term mortality.37Nature Reviews Disease Primers. Acute-on-chronic liver failure in cirrhosis Recognizing ACLF early is critical because it changes management from outpatient monitoring to intensive care, and may accelerate the transplant evaluation timeline.
Pulmonary Complications of Cirrhosis
The lungs are not immune to the effects of cirrhosis. Hepatopulmonary syndrome (HPS) occurs when microscopic blood vessels in the lungs dilate, allowing blood to pass through without properly picking up oxygen. Patients develop shortness of breath, particularly when standing or sitting upright, and may have low oxygen levels on pulse oximetry. Contrast-enhanced echocardiography (a “bubble study”) is the standard test for detecting the intrapulmonary shunting that defines HPS. Portopulmonary hypertension, a different condition in which pulmonary artery pressure rises in the setting of portal hypertension, requires right heart catheterization to confirm. The two can look similar clinically but demand different treatments, and missing the distinction has real consequences.38PubMed Central. Differential diagnosis of hepatopulmonary syndrome (HPS): Portopulmonary hypertension (PPH) and hereditary hemorrhagic telangiectasia (HHT)
Delays and Gaps in the Diagnostic Process
From the patient side, the cirrhosis workup does not always go smoothly. A national survey of people with liver disease found that fewer than one in five were diagnosed at an early stage, while about 14% felt their diagnosis was delayed until the disease had progressed significantly. Nearly a third reported delays in getting referred to a specialist, and about the same proportion said they were not seen promptly when they needed urgent advice.39Gut. Results of a national survey of patient experience and satisfaction with care of liver disease A quarter of respondents reported feeling stigmatized by medical professionals, a particular concern in alcohol-related liver disease where stigma can discourage people from seeking care in the first place. These findings suggest that even with effective diagnostic tools available, systemic barriers around access, referral speed, and clinician attitudes still shape how and when cirrhosis gets diagnosed in practice.